证券代码：600511 证券简称：国药股份 公告编号：2023-029 国药集团药业股份有限公司 2023 年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 24 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 26,546,816 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 7.7699 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事会召集，董事长姜修昌先生主持，会议采用现场投票和网络 投票的方式进行表决，符合《公司法》及《公司章程》的规定。 (一) 股东大会召开的时间：2023 年 9 月 8 日 (二) 股东大会召开的地点：北京市东城区永定门西滨河路 8 号院中海地产广 场西塔 8 层会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其 ...

国浩律师（北京）事务所 关于国药集团药业股份有限公司 2023 年第二次临时股东大会律师见证之 法律意见书 北京 上海 深圳 杭州 天津 昆明 广州 成都 宁波 福州 西安 南京 南宁 济南 重庆 香港 巴黎 马德里 硅谷 地址：北京市朝阳区东三环北路38号泰康金融大厦9层 邮编：100026 电话：010-65890699 传真：010-65176800 网址：http://www.grandall.com.cn 2023 年 9 月 致：国药集团药业股份有限公司 国浩律师（北京）事务所 关于国药集团药业股份有限公司 2023年第二次临时股东大会律师见证之 法律意见书 国浩京证字[2023]第0759号 根据本次股东大会的会议通知，本次股东大会由公司董事会召集。 （二）本次股东大会的召集 根据国药集团药业股份有限公司（下称"公司"）的委托，并依据《中华人民 共和国公司法》（下称"《公司法》"）、《中华人民共和国证券法》（下称"《证 券法》"）和中国证券监督管理委员会发布的《上市公司股东大会规则》（下称"《股 东大会规则》"）、《上市公司治理准则》（下称"《治理准则》"）等法律、行 政法规、规范性文件以及《国 ...

国药集团药业股份有限公司 2023 年第二次临时股东大会会议资料 国药股份 2023 年第二次临时股东大会议程 现场会议时间：2023 年 9 月 8 日 9:30 股票代码：600511 2023 年 9 月 8 日 交易系统平台网络投票时间： 2023 年 9 月 8 日 9:15-9:25，9:30-11:30，13:00-15:00； 互联网投票平台网络投票时间： 2023 年 9 月 8 日 9:15-15:00 现场会议地点：北京市东城区永定门西滨河路 8 号院中 海地产广场西塔 8 层会议室 会议议题： 国药股份关于国药集团财 务有限公司拟为公司提供金融 服务暨关联交易的议案 2 国药集团药业股份有限公司 关于国药集团财务有限公司拟为公司 提供金融服务暨关联交易的议案 各位股东： 一、关联交易概述 1、基本情况 为优化公司财务管理、提高资金使用效率、拓宽融资渠道、降低融资成本和 融资风险，提高风险管控能力、有效降低公司的财务费用及资金成本，公司与国 药财务经友好协商，遵循"平等、自愿、互利、互惠、诚信"的原则，达成合作 意向，拟由国药财务为公司及下属子公司提供存款、贷款、结算及经中国银行保 险监 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥24,140,175,654.64, representing a 9.70% increase compared to ¥22,006,490,053.03 in the same period last year[14]. - Net profit attributable to shareholders of the listed company was ¥984,583,170.50, up 14.19% from ¥862,246,884.87 in the previous year[14]. - The net profit after deducting non-recurring gains and losses was ¥951,127,923.58, reflecting an 11.21% increase from ¥855,290,137.50 year-on-year[14]. - Basic earnings per share for the first half of 2023 were ¥1.3049, up 14.19% from ¥1.1428 in the same period last year[15]. - The company reported a total comprehensive income of ¥1,063,436,548.83, compared to ¥935,328,068.99 in the same period last year, reflecting an increase of 13.7%[107]. - The total profit for the period was ¥1,324,508,245.18, up from ¥1,185,573,737.51 in the same period of 2022, marking a growth of 11.7%[106]. - The company reported a net profit margin improvement, with net profit for the first half of 2023 reflecting a positive trend compared to the previous year[105]. Cash Flow and Financial Position - The net cash flow from operating activities decreased significantly to -¥166,057,140.22, a decline of 575.27% compared to ¥34,939,821.40 in the same period last year[14]. - The company reported cash and cash equivalents at the end of the period amounting to approximately ¥7.75 billion, an increase from ¥6.71 billion at the end of the previous year[113]. - The company incurred a net cash outflow from financing activities of approximately ¥862.03 million, compared to a net outflow of ¥518.56 million in the same period of 2022[113]. - The net cash flow from operating activities for the first half of 2023 was ¥594,344,593.37, a decrease of 34.8% compared to ¥911,487,318.43 in the same period of 2022[114]. - The company reported a cash balance of approximately CNY 7.81 billion as of June 30, 2023, compared to CNY 8.90 billion at the end of 2022, indicating a decrease of about 12.2%[99]. - The total current assets reached CNY 26.98 billion, an increase from CNY 25.76 billion, representing a growth of about 4.7%[99]. Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥30,839,517,312.09, which is a 4.16% increase from ¥29,609,041,999.59 at the end of the previous year[14]. - The total liabilities increased to ¥14,508,680,841.58 from ¥13,749,571,981.97, marking an increase of approximately 5.51%[101]. - Current liabilities rose to ¥13,536,161,921.91 from ¥12,739,590,053.94, representing an increase of about 6.26%[100]. - Accounts receivable increased to CNY 6.39 billion, up from CNY 5.75 billion, reflecting a growth of approximately 11.2% year-over-year[99]. - The company's retained earnings rose to ¥10,872,503,090.27 from ¥10,479,854,338.41, reflecting an increase of about 3.75%[101]. Market Position and Business Operations - The company has achieved 100% coverage of grade hospitals in Beijing and has established relationships with over 4,700 grassroots medical institutions[20]. - The company maintains a leading market share in the national wholesale business of narcotic drugs and class I psychotropic drugs, covering over 50,000 medical clients nationwide[23]. - The company has strengthened its retail direct sales business, covering over 30,000 stores and extending its reach to more than 220,000 terminal pharmacies[20]. - The company is exploring new cooperation models in narcotic drug distribution and enhancing intelligent management solutions for upstream and downstream clients[29]. - The company is focusing on innovation in service delivery, transitioning from pure drug sales to providing comprehensive pharmaceutical solutions[28]. Compliance and Risk Management - The company reported no significant risk events during the reporting period[4]. - There were no non-operating fund occupations by controlling shareholders or related parties[3]. - The company faces risks including policy changes affecting drug pricing and market competition impacting sustainable development[48]. - The company is actively enhancing its compliance operations as a core competitive advantage[25]. Environmental and Sustainability Efforts - The company has obtained a new wastewater discharge permit valid from August 17, 2022, to August 16, 2027, primarily managing air emissions[54]. - The company has seven pollution control facilities that are maintained regularly, with a focus on meeting environmental protection requirements[57]. - The company has implemented a VOCs online monitoring system in the raw material workshop to ensure compliance with emission standards[57]. - The company reduced carbon emissions by 623 tons in the first half of 2023 through various measures, including stable operation of the wastewater treatment system, which saved 112,332 tons of water[68]. - The company is actively responding to carbon reduction goals by implementing energy-saving technologies and practices[68]. Research and Development - R&D expenses increased by 15.12% to ¥34,337,438.64, up from ¥29,826,674.03 in the previous year[35]. - The company is focused on research and development of new products and technologies to maintain competitive advantage in the market[125]. - The company has introduced children's orthodontic products, marking a significant step into the pediatric dental management field[30]. Shareholder and Capital Management - The company did not propose any profit distribution or capital reserve increase for the first half of 2023[52]. - The total number of shares held by China National Pharmaceutical Group Corporation is 412,841,745, accounting for 54.72% of the total shares[92]. - The company completed a share repurchase of 2,529,307 shares due to unmet performance commitments, reducing the total share capital to RMB 764,404,391[127]. - The company has undergone significant changes in its shareholding structure, with the controlling shareholder being China National Pharmaceutical Group Co., Ltd. holding 55.29% of the shares[126]. Accounting and Financial Reporting - The financial statements are prepared based on the going concern principle and comply with the accounting standards issued by the Ministry of Finance[130]. - The company has specific accounting policies for bad debt provisions, inventory valuation, and impairment testing for long-term assets[131]. - The company recognizes financial assets or liabilities upon entering into a financial instrument contract[140]. - The company applies the expected credit loss model for assessing impairment of financial instruments, which requires significant judgment and estimation based on historical repayment data and macroeconomic indicators[188].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600511 证券简称：国药股份 公告编号：2023-022 国药集团药业股份有限公司 2023 年第一次临时股东大会决议公告 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2023 年 8 月 18 日 (二) 股东大会召开的地点：北京 市 东城 区 永定 门西 滨 河路 8 号院 中海 地产 广 场西 塔 8 层 会议 室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (五) 公司董事、监事和董事会秘书的出席情况 3、董事会秘书出席本次会议；其他部分高管列席会议。 二、 议案审议情况 (一) 非累积投票议案 1、 议案名称：公司关于变更 2023 年度会计师事务所的议案 | 1、出席会议的股东和代理人人数 | 12 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 423,159,400 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | ...

2023 年第一次临时股东大会律师见证之 法律意见书 國浩律師(北京)事務所 GRANDALL LAW FIRM (BEIJING) 北京 上海 深圳 杭州 天津 昆明 广州 成都 宁波 福州 西安 南京 南宁 济南 重庆 香港 巴黎 马德里 硅谷 地址:北京市朝阳区东三环北路38号泰康金融大厦9层 邮编:100026 电话:010-65890699 传真:010-65176800 网址: http://www.grandall.com.cn 2023年8月 国浩律师(北京)事务所 关于国药集团药业股份有限公司 M(北京) 争 務 所 LAW FIRM (BF). 致:国药集团药业股份有限公司 国浩律师(北京)事务所 关于国药集团药业股份有限公司 2023年第一次临时股东大会律师见证之 法律意见书 国浩京证字[2023]第0743号 根据国药集团药业股份有限公司(下称"公司")的委托,并依据《中华人民 共和国公司法》(下称"《公司法》")、《中华人民共和国证券法》(下称"《证 券法》")和中国证券监督管理委员会发布的《上市公司股东大会规则》(下称"《股 东大会规则》")、《上市公司治理准则》(下称"《治理准则 ...

国药集团药业股份有限公司 2023 年第一次临时股东大会会议资料 股票代码：600511 2023 年 8 月 18 日 国药股份 2023 年第一次临时股东大会议程 现场会议时间：2023 年 8 月 18 日 9:30 交易系统平台网络投票时间： 2023 年 8 月 18 日 9:15-9:25，9:30-11:30，13:00-15:00； 互联网投票平台网络投票时间： 2023 年 8 月 18 日 9:15-15:00 现场会议地点：北京市东城区永定门西滨河路 8 号院中 海地产广场西塔 8 层会议室 会议议题： 国药股份关于变更 2023 年度会计师事务所的议案 2 各位股东： 一、拟聘任会计师事务所的基本情况 （一）机构信息 一、国药股份关于变更 2023 年度会计师事务所 的议案 3 国药集团药业股份有限公司 关于变更 2023 年度会计师事务所的议案 1.基本信息 普华永道中天前身为 1993 年 3 月 28 日成立的普华大华会计师事 务所，经批准于 2000 年 6 月更名为普华永道中天会计师事务所有限 公司；经 2012 年 12 月 24 日财政部财会函[2012]52 号批准，于 ...

证券代码：600511 证券简称：国药股份 公告编号：临 2023-016 投资者可于 2023 年 05 月 11 日(星期四) 至 05 月 17 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 gygfzqb@sinopharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 国药集团药业股份有限公司（以下简称"公司"）已于 2023 年 3 月 23 日发 布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度暨 2023年第一季度经营成果、财务状况，公司计划于2023年05月18日16:00-17:00 举行 2022 年度暨 2023 年第一季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度暨 2023 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 国药集团药业股份有限公司关于召开 2022 年度暨 2023 年第一季度业绩 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥11,226,301,799.68, representing a year-on-year increase of 1.50%[4] - The net profit attributable to shareholders for Q1 2023 was ¥414,428,624.82, reflecting a growth of 10.86% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥412,594,479.98, an increase of 11.99% year-on-year[4] - The basic and diluted earnings per share for Q1 2023 were both ¥0.5493, up by 10.86% from the previous year[5] - The company reported a net profit margin improvement, with net profit for the quarter expected to be higher than the previous year, although specific figures were not disclosed[16] - The net profit for Q1 2023 was CNY 450,428,720.64, an increase of 10% compared to CNY 409,527,036.98 in Q1 2022[18] - The company reported a total profit of CNY 574,092,850.97, which is an increase of 9.3% from CNY 524,834,951.41 in the same quarter last year[18] - Total comprehensive income for the period was CNY 454,509,100.02, compared to CNY 409,330,053.15 in the previous year, reflecting an increase of about 11%[19] - The company reported a total comprehensive income of CNY 283,206,166.14, up from CNY 241,844,242.71 in the previous year, marking an increase of approximately 17.1%[27] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to ¥29,973,102,161.98, a 1.23% increase from the end of the previous year[5] - The total assets as of March 31, 2023, amounted to RMB 29,973,102,161.98, up from RMB 29,609,041,999.59 at the end of 2022, representing a growth of approximately 1.2%[14] - Total liabilities decreased to RMB 13,659,123,044.34 from RMB 13,749,571,981.97, a reduction of about 0.7%[14] - The total liabilities decreased to CNY 9,040,422,614.32 in Q1 2023 from CNY 10,069,654,647.71 in Q1 2022, a reduction of about 10.2%[25] - The equity attributable to shareholders at the end of Q1 2023 was ¥14,633,316,663.59, which is a 2.94% increase compared to the end of the previous year[5] - The company's total equity increased to CNY 12,146,291,487.66 in Q1 2023 from CNY 11,863,085,321.52 in Q1 2022, reflecting a growth of approximately 2.4%[25] Cash Flow - The net cash flow from operating activities for Q1 2023 was negative at -¥1,144,417,344.84, indicating a significant cash outflow[4] - Cash flow from operating activities showed a net outflow of CNY -1,144,417,344.84, an improvement from CNY -1,309,048,043.82 in the previous year[21] - The net cash flow from financing activities was CNY 161,784,331.64 in Q1 2023, compared to a negative cash flow of CNY -134,322,698.79 in Q1 2022[22] - The cash inflow from financing activities was CNY 372,033,932.97, compared to CNY 346,761,757.81 in the previous year, representing an increase of about 7.3%[21] - The cash inflow from financing activities was CNY 4,622,866,991.24, an increase from CNY 3,899,604,840.39 in the same quarter last year, showing a growth of about 18.5%[28] - The company experienced a decrease in cash outflow from financing activities, which totaled CNY 5,651,665,054.86, compared to CNY 5,124,025,846.95 in Q1 2022, indicating a rise of approximately 10.3%[28] Operational Metrics - Total operating costs for Q1 2023 were RMB 10,721,710,525.39, compared to RMB 10,588,273,902.20 in Q1 2022, reflecting an increase of about 1.3%[16] - The total revenue from operating activities was CNY 11,269,856,654.00, down from CNY 11,677,534,959.21 in the previous year, representing a decrease of approximately 3.5%[21] - The total revenue from operating activities was CNY 5,368,466,798.45, compared to CNY 5,219,032,090.91 in the same period last year, indicating a year-over-year increase of about 2.86%[28] - The company recorded investment income of CNY 80,674,195.75, up from CNY 54,601,163.95, indicating a growth of approximately 47.7%[18] - Research and development expenses increased to CNY 16,684,728.20, up from CNY 13,439,599.79, reflecting a growth of about 24%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 58,530[8] - The largest shareholder, China National Pharmaceutical Group Co., Ltd., held 54.72% of the shares[9]

Financial Performance - The company's operating revenue for 2022 was CNY 45.50 billion, a decrease of 2.09% compared to CNY 46.47 billion in 2021[14]. - Net profit attributable to shareholders was CNY 1.96 billion, an increase of 11.97% from CNY 1.75 billion in 2021[14]. - The net cash flow from operating activities increased by 22.36% to CNY 2.40 billion, compared to CNY 1.96 billion in 2021[14]. - The company's total assets at the end of 2022 were CNY 29.61 billion, reflecting a 5.71% increase from CNY 28.01 billion in 2021[14]. - Basic earnings per share for 2022 were CNY 2.60, up 11.97% from CNY 2.32 in 2021[15]. - The weighted average return on equity increased to 14.65%, up 0.08 percentage points from 14.57% in 2021[15]. - The company achieved a total revenue of 45.499 billion RMB in 2022, a decrease of 2.09% year-on-year[39]. - Net profit for the year was 2.129 billion RMB, reflecting a year-on-year increase of 10.38%[39]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 7.82 RMB per 10 shares, totaling approximately 590 million RMB, based on a total share capital of 754,502,998 shares as of December 31, 2022[3]. - The net profit attributable to the parent company for 2022 is 1,964,057,559.33 RMB[104]. - The total equity attributable to the parent company at the end of 2022 was approximately CNY 12.78 billion, a decrease of CNY 867,794.78 compared to the previous year[196]. Governance and Compliance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[2]. - The company has a comprehensive governance structure in place, with all board members present at the board meeting[2]. - The governance structure has been improved to ensure compliance with regulations and enhance operational efficiency[68]. - The company has established a clear and independent governance structure, ensuring that the controlling shareholder does not interfere in decision-making or operational activities[69]. - The company has implemented a performance evaluation and incentive mechanism for senior management, ensuring accountability and alignment with shareholder interests[69]. - The company has successfully completed significant asset restructuring, with announcements made regarding the completion of asset transfers in 2017[69]. Risk Management - The company has detailed potential risks in its management discussion and analysis section, which investors should review[4]. - The company faces risks from policy changes, particularly in drug pricing and procurement, which could compress profit margins in the pharmaceutical distribution sector[66]. - Market competition and new entrants pose risks to the company's competitive advantage and long-term sustainability[67]. - The company has strengthened compliance management and risk control, focusing on financial indicators and enhancing management efficiency[31]. Research and Development - The company’s R&D expenses increased by 20.17% to approximately 67 million RMB, indicating a strong focus on new product development[40]. - The company registered 9 new drug certificates and passed consistency evaluations for 7 products in 2022[38]. - The company is investing heavily in R&D, with a budget increase of 25% to enhance product innovation and technology[78]. - Research and development investments increased by 30%, focusing on advanced drug delivery systems and biotechnology[81]. Market and Business Strategy - The company emphasized its commitment to high-quality development and expansion into new fields and products in 2022[21]. - The company is actively pursuing digital transformation, establishing a dedicated organization and conducting research to enhance digital management capabilities[30]. - The company is transitioning from traditional pharmaceutical distributors to high-quality, comprehensive medical supply chain service providers[63]. - The company plans to strengthen its distribution business through new product introductions and innovative services to ensure steady growth[65]. Environmental Responsibility - The company invested 48.3232 million RMB in environmental protection during the reporting period[110]. - The company has established an emergency response plan for environmental incidents, focusing on the management and safety of hazardous chemicals[116]. - The company is committed to environmental responsibility, with no administrative penalties reported for environmental issues during the reporting period[122]. - The company reduced carbon emissions by 405 tons through the implementation of low-carbon technologies in production processes[124]. Employee and Compensation Information - The total pre-tax compensation for the chairman was 221.25 million CNY, while the general manager received 164.6877 million CNY[75]. - The total pre-tax compensation for the independent directors averaged 13.3336 million CNY each, with a total of 53.3344 million CNY for four independent directors[75]. - The company has a competitive salary system aimed at aligning employee benefits with company performance[101]. - The total number of employees in the parent company and major subsidiaries is 3,080, with 550 in the parent company and 2,530 in subsidiaries[99]. Audit and Financial Reporting - The company's financial statements have been audited and reflect a fair view of its financial position as of December 31, 2022[168]. - The audit report confirms compliance with Chinese accounting standards, ensuring the reliability of the financial data presented[168]. - The audit firm emphasizes the importance of evaluating management's use of accounting policies and estimates, particularly regarding the going concern assumption[176]. Related Party Transactions - The actual amount of related party transactions for sales and services in 2022 was CNY 5.01 billion, which did not exceed the expected CNY 6.79 billion[139]. - The company has committed to resolving competition issues with its controlling shareholder, aiming for a comprehensive solution within five years[69]. - The company will ensure that any unavoidable related party transactions are conducted on fair and reasonable commercial terms[132].